Abstract: A use of D-arabitol in lipid-lowering and hepatoprotection is provided. Blood or liver lipid abnormalities refer to abnormalities in a quantity and a quality of lipids in the blood or liver, and usually refer to the elevation of cholesterol and/or triglycerides (TGs). Blood and liver lipid abnormalities can lead to atherosclerosis, increase the morbidity and mortality rates of cardio-cerebrovascular diseases, and cause the liver damage. D-arabitol has an excellent lipid-lowering and hepatoprotective effect, and has a prospect of being developed into a drug or health care product or food for lipid-lowering and hepatoprotection.

Abstract: An ultrasound phased array integrated in flexible CMOS technology is provided. The CMOS IC chip is fabricated through various chip-thinning techniques, resulting in mechanical flexibility, robustness, and minimized mechanical loading for the piezoelectric transducers. The ultrasound phased array CMOS patch can allow for the generation of high intensity focal regions for maximum penetration in regions of interest.

Abstract: Provided are an ROR?t modulator, and a preparation method therefor and an application thereof. The ROR?t modulator is selected from a compound represented by formula I, and a pharmaceutically acceptable salt, solvate, solvate of pharmaceutically acceptable salt, metabolite or prodrug thereof. The compound has inhibitory activity on ROR?t, and can effectively inhibit an ROR?t protein receptor, thereby regulating the differentiation of Th17 cells, inhibiting generation of IL-17, and then treating ROR?t-mediated relevant autoimmune diseases.

Abstract: An ultrasound phased array integrated in flexible CMOS technology is provided. The CMOS IC chip is fabricated through various chip-thinning techniques, resulting in mechanical flexibility, robustness, and minimized mechanical loading for the piezoelectric transducers. The ultrasound phased array CMOS patch can allow for the generation of high intensity focal regions for maximum penetration in regions of interest.

Abstract: A surface coating for degradable magnesium and magnesium alloys, including: an inner layer and an outer layer. The inner layer is a magnesium phosphate conversion layer, and the outer layer is a hydroxyapatite layer. A method for fabricating the surface coating is also provided herein, which includes: soaking the magnesium or magnesium alloy in an acidic solution containing magnesium salt and phosphate under heating to form the magnesium phosphate conversion layer on a surface of the magnesium or magnesium alloy; and transferring the magnesium or magnesium alloy to an alkaline solution containing calcium salt and phosphate followed by soaking under heating to form a hydroxyapatite layer on a surface of the magnesium phosphate conversion layer.

Abstract: A coating with strong adhesion for medical magnesium alloys, including a magnesium phosphate or calcium phosphate layer as an inner layer and a hydrophobic polymer layer as an outer layer. The inner layer is attached to the medical magnesium alloy; and the outer layer is attached to the inner layer. A preparation method of the coating is also provided, including: (S1) carrying out surface treatment on a medical magnesium alloy substrate; (S2) preparing a solution including magnesium salt/calcium salt and phosphoric acid/phosphate followed by pH adjustment and heating; (S3) soaking the medical magnesium alloy substrate in the solution followed by washing and drying to obtain a magnesium phosphate/calcium phosphate layer-coated medical magnesium alloy sample; and (S4) depositing a hydrophobic polymer layer on the medical magnesium alloy sample through chemical vapor deposition (CVD).

Abstract: Methods and systems may be configured to verify proper installation of Internet Protocol (IP) connectable building automation devices by installers at remote sites. The installers may be a crowdsourced installers. A service provider may engage an installer to install one or more IP connectable building automation devices. To ensure verification that the one or more IP connectable building automation devices are installed properly, parameters or values based on data from installed IP connectable building automation devices may be provided to or determined by a blockchain network. The blockchain network may compare the parameters or values to thresholds and automatically provide an indication as to whether the parameters or values meet or exceed the thresholds (e.g., verification criteria).

Abstract: Disclosed in the present invention are a pyrazolone-fused pyrimidine compound, and a preparation method and a use therefor. Provided in the present invention is a pyrazolone-fused pyrimidine compound as in formula (I), said compound having better inhibitory activity towards WEE1 kinase.

Abstract: Disclosed are a pyrazolone-fused pyrimidine compound, a preparation method for same and applications thereof. Provided in the present invention is the pyrazolone-fused pyrimidine compound as represented by formula (II). The compound has improved inhibitory activity with respect to WEE1 kinase.

Abstract: Methods and systems may be configured to verify proper installation of Internet Protocol (IP) connectable building automation devices by installers at remote sites. The installers may be a crowdsourced installers. A service provider may engage an installer to install one or more IP connectable building automation devices. To ensure verification that the one or more IP connectable building automation devices are installed properly, parameters or values based on data from installed IP connectable building automation devices may be provided to or determined by a blockchain network. The blockchain network may compare the parameters or values to thresholds and automatically provide an indication as to whether the parameters or values meet or exceed the thresholds (e.g., verification criteria).

Abstract: Methods and systems may be configured to verify proper installation of Internet Protocol (IP) connectable building automation devices by installers at remote sites. The installers may be a crowdsourced installers. A service provider may engage an installer to install one or more IP connectable building automation devices. To ensure verification that the one or more IP connectable building automation devices are installed properly, parameters or values based on data from installed IP connectable building automation devices may be provided to or determined by a blockchain network. The blockchain network may compare the parameters or values to thresholds and automatically provide an indication as to whether the parameters or values meet or exceed the thresholds (e.g., verification criteria).

Abstract: An integrated motor drive includes a frame assembly, a motor, a motor driver and a heat dissipation assembly. The frame assembly includes a first frame and a second frame. The motor is installed on the first frame. The motor driver is installed on the second frame. The heat dissipation assembly includes a motor heat exchange pipe, a motor driver heat exchange pipe, and a heat dissipation pipe. The motor heat exchange pipe is embedded in the first frame, and located at one side portion of the motor for performing heat exchange with the motor. The motor driver heat exchange pipe is embedded in the second frame for performing heat exchange with the motor driver. The heat dissipation pipe is located at an end portion of the motor, and communicated with the motor heat exchange pipe and the motor driver heat exchange pipe.

Abstract: The present invention discloses a substituted pyridine compound represented by formula I, and a pharmaceutically acceptable salt, stereoisomer and tautomer thereof. The compounds of the present invention are useful in the treatment of cancers.

Abstract: Methods and systems may be configured to verify proper installation of Internet Protocol (IP) connectable building automation devices by installers at remote sites. The installers may be a crowdsourced installers. A service provider may engage an installer to install one or more IP connectable building automation devices. To ensure verification that the one or more IP connectable building automation devices are installed properly, parameters or values based on data from installed IP connectable building automation devices may be provided to or determined by a blockchain network. The blockchain network may compare the parameters or values to thresholds and automatically provide an indication as to whether the parameters or values meet or exceed the thresholds (e.g., verification criteria).

Abstract: Apparatus and methods for powering micron-scale implantable and injectable integrated circuit (IC) chips for in-vivo sensing and acquisition of various physiological signals are provided. The disclosed subject matter includes the integration of piezoelectric transducers, such as polyvinylidene fluoride (PVDF) or lead zirconate titanate (PZT), onto implantable and injectable IC chips for power transfer and data transmission using ultrasound waves generated from commercial ultrasound imaging equipment.

Abstract: A motor sleeve is applied to a motor housing and a motor driver housing. The motor sleeve includes a sleeve base, a second fixing structure, a second coupling structure, a plurality of base fins, a sleeve chassis, a plurality of chassis fins, and a third fixing structure. The second fixing structure is disposed on an inner surface of the sleeve base and correspondingly fixed to a first fixing structure of the motor housing. The sleeve base is installed on a lateral portion of the motor housing. The base fins are separately disposed on an outer surface of the sleeve base and corresponding to a first coupling structure of the motor driver housing. The motor driver housing is coupled to the sleeve base by the first and second coupling structures. The third fixing structure is correspondingly fixed to a fourth fixing structure of the motor housing.

Abstract: A motor sleeve is applied to a motor housing and a motor driver housing. The motor sleeve includes a sleeve base, a second fixing structure, a second coupling structure and a plurality of base fins. The sleeve base includes an outer surface and an inner surface. The second fixing structure is disposed on the inner surface and located corresponding to a first fixing structure of the motor housing. The sleeve base is fixed to the motor housing by the first and second fixing structures. The sleeve base is installed on a side portion of the motor housing. The second coupling structure is disposed on the outer surface. The base fins are separately disposed on the outer surface and located corresponding to a first coupling structure of the motor driver housing. The motor driver housing is coupled to the sleeve base by the first and second coupling structures.

Abstract: The present invention discloses a substituted pyridine compound represented by formula I, and a pharmaceutically acceptable salt, stereoisomer and tautomer thereof. The compounds of the present invention are useful in the treatment of cancers.

Abstract: A motor device includes a motor, a motor driver housing, a motor control circuit board, a heat dissipation device, a heat isolation element and at least one fixing element. The motor includes fins arranged at a lateral portion of the motor. The motor driver housing includes a bottom surface. A gap is provided between the bottom surface and the lateral portion. The heat dissipation device is disposed at an end portion of the motor. The heat dissipation device includes a heat dissipation housing and a single fan. The heat dissipation housing includes an inlet and a first outlet. The first outlet faces the gap. The fan is disposed in the heat dissipation housing. The heat isolation element is connected to the motor and the heat dissipation housing. The fixing element passes through the heat isolation element and fixes the heat dissipation housing to the end portion of the motor.

Abstract: The present invention discloses a nitrogen-containing fused heterocyclic compound, as well as a preparation method, intermediate, composition and application thereof. The nitrogen-containing fused heterocyclic compound of the present invention as represented by formula (I), as well as the pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, metabolite or drug precursor thereof, exhibit a high selectivity and a high inhibitory activity with respect to CDK4 and CDK6 at a molecular level, an excellent inhibitory activity with respect to breast cancer cells at a cellular level, and significant inhibition of tumor cell proliferation associated with cyclin-dependent kinase activity at an animal level. The invention also exhibits a good stability with respect to human or mouse liver microsomes without significant inhibition of metabolic enzymes, good in vivo absorption in mice and rats, a high bioavailability and good druggability.